checkAd
    Corbus Pharmaceuticals Holdings Aktie
    34,08
     
    USD
    +1,73 %
    +0,58 USD
    Letzter Kurs 21:18:03 Nasdaq
    33,92
     
    USD
    200 STK
    Geldkurs 21:19:19
    34,20
     
    USD
    100 STK
    Briefkurs 21:19:19
    ISIN: US21833P3010 · WKN: A3D54P · SYM: CRBP · USA

    Neueste Nachrichten

    Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
    24.04.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
    02.04.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
    12.03.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
    06.03.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
    28.02.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    06.02.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
    02.02.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals Announces Pricing of Public Offering
    31.01.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals Announces Proposed Public Offering
    31.01.24 · globenewswire · Corbus Pharmaceuticals Holdings
    CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
    26.01.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
    23.01.24 · globenewswire · Corbus Pharmaceuticals Holdings
    Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
    09.01.24 · globenewswire · Corbus Pharmaceuticals Holdings